Last week, CSL heard from the Federal Trade Commission that the agency is opposed to CSL’s proposed $3.1 billion merger with Talecris Biotherapeutics.
Don’t worry, CSL, Health and Human Services still loves you. To the tune of a $180 million order for CSL’s H1N1 swine flu vaccine bulk antigen. HHS will also fund the clinical trials.
